Compare PFAI & BOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PFAI | BOLD |
|---|---|---|
| Founded | 2015 | 2018 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Farming/Seeds/Milling | |
| Sector | Consumer Staples | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 27.1M | 26.2M |
| IPO Year | 2025 | 2024 |
| Metric | PFAI | BOLD |
|---|---|---|
| Price | $2.28 | $1.16 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $4.00 |
| AVG Volume (30 Days) | 8.6K | ★ 185.6K |
| Earning Date | 12-26-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $3,497,672.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 28.80 | N/A |
| 52 Week Low | $1.30 | $1.00 |
| 52 Week High | $4.93 | $3.45 |
| Indicator | PFAI | BOLD |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 47.85 |
| Support Level | N/A | $1.11 |
| Resistance Level | N/A | $1.20 |
| Average True Range (ATR) | 0.00 | 0.07 |
| MACD | 0.00 | 0.01 |
| Stochastic Oscillator | 0.00 | 80.00 |
Pinnacle Food Group Ltd is a provider of smart farming solutions focused on vertical and hydroponic farming. The company focuses on promoting sustainable food security by developing and building customized smart farming systems for customers based on the systematic integration of technology, hardware, and software, coupled with a full range of integrated supply and technical services. It sells hydroponic growing systems and technical support services to individual households and community groups, and is developing a hydroponic growing system for urban farms. Geographically, the company generates the majority revenue from Canada, followed by New Zealand.
Boundless Bio Inc is a clinical-stage oncology company. The company is dedicated to unlocking a new paradigm in cancer therapeutics that addresses the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Its ecDTx, BBI-355, is a novel, oral, selective inhibitor of checkpoint kinase 1 (CHK1), which manages ecDNA replication and transcription in cancer cells.